Segment Data (Tables)

12 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Areas

Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.  As discussed in Note 10, the Company completed its acquisition of Bard on December 29, 2017. Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018.

(Millions of dollars)	2019						2018						2017
	United States		International		Total		United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	2,048	$	1,811	$	3,859	$	1,892	$	1,752	$	3,644	$	1,378	$	1,434	$	2,812
Medication Management Solutions	2,104		525		2,629		1,957		513		2,470		1,843		452		2,295
Diabetes Care	573		538		1,110		564		541		1,105		546		510		1,056
Pharmaceutical Systems	392		1,073		1,465		357		1,040		1,397		328		929		1,256
Total segment revenues	$	5,116	$	3,947	$	9,064	$	4,770	$	3,846	$	8,616	$	4,095	$	3,325	$	7,419
Life Sciences
Preanalytical Systems	$	774	$	784	$	1,558	$	761	$	792	$	1,553	$	741	$	730	$	1,471
Diagnostic Systems	672		875		1,547		678		858		1,536		622		756		1,378
Biosciences	485		709		1,194		475		766		1,241		455		684		1,139
Total segment revenues	$	1,931	$	2,368	$	4,300	$	1,914	$	2,416	$	4,330	$	1,818	$	2,170	$	3,988
Interventional
Surgery (a)	$	1,098	$	299	$	1,397	$	946	$	245	$	1,192	$	577	$	89	$	666
Peripheral Intervention (a)	787		602		1,389		594		451		1,045		14		6		19
Urology and Critical Care	797		342		1,140		544		256		800		—		—		—
Total segment revenues	$	2,682	$	1,244	$	3,926	$	2,084	$	953	$	3,037	$	591	$	95	$	685
Total Company revenues	$	9,730	$	7,560	$	17,290	$	8,768	$	7,215	$	15,983	$	6,504	$	5,589	$	12,093

(a)Amounts presented in 2017 are associated with certain product offerings that were moved from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018.

Financial Information for Company's Segments

(Millions of dollars)	2019			2018			2017
Income Before Income Taxes
Medical (a) (b) (c)	$	2,824		$	2,624		$	1,907
Life Sciences (d)	1,248			1,207			772
Interventional (b) (e) (f)	903			306			248
Total Segment Operating Income	4,976			4,137			2,927
Acquisitions and other restructurings	(480		)	(740		)	(354		)
Net interest expense	(627		)	(641		)	(445		)
Other unallocated items (g)	(2,693		)	(1,583		)	(1,152		)
Total Income Before Income Taxes	$	1,176		$	1,173		$	976
Assets
Medical	$	22,925		$	23,493		$	15,552
Life Sciences	4,135			4,225			4,056
Interventional (f)	22,157			23,219			2,780
Total Segment Assets	49,217			50,938			22,388
Corporate and All Other (h)	2,548			2,966			15,347
Total Assets	$	51,765		$	53,904		$	37,734
Capital Expenditures
Medical	$	577		$	560		$	486
Life Sciences	230			255			212
Interventional (f)	120			65			16
Corporate and All Other	30			14			13
Total Capital Expenditures	$	957		$	895		$	727
Depreciation and Amortization
Medical	$	1,073		$	1,028		$	773
Life Sciences	284			275			254
Interventional (f)	881			658			52
Corporate and All Other	14			17			10
Total Depreciation and Amortization	$	2,253		$	1,978		$	1,088

(a)The amount in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.

(b)The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments in 2018 were $60 million and $418 million, respectively.

(c)The amount in 2018 included $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit.

(d)The amount in 2018 included $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit.

(e)The amount in 2019 included a charge of $30 million recorded to write down the carrying value of certain intangible assets in the Surgery unit.

(f)Amounts presented in 2017 are associated with certain product offerings that were moved from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018.

(g)Primarily comprised of foreign exchange, corporate expenses, and share-based compensation expense. The amount in 2019 included a pre-tax charge of $914 million related to certain product liability matters, which is further discussed in Note 5, and also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million, which is further discussed in Note 11. Results in 2019 and 2018 were impacted by the Company's change in its management reporting approach, as further discussed above. The amount in 2018 included the pre-tax gain recognized on the Company's sale of its non-controlling interest in Vyaire Medical of approximately $303 million. Results in 2017 included a $748 million non-cash charge resulting from a modification to the Company's dispensing equipment lease contracts with customers, as well as the reversal of certain litigation reserves. 

(h)Includes cash and investments and corporate assets.

Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment

Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.

(Millions of dollars)	2019		2018		2017
Revenues
United States	$	9,730	$	8,768	$	6,504
Europe	3,359		3,298		2,588
Greater Asia	2,726		2,460		1,744
Other	1,476		1,457		1,257
	$	17,290	$	15,983	$	12,093
Long-Lived Assets
United States	$	37,053	$	38,982	$	13,151
Europe	5,483		5,640		4,421
Greater Asia	1,328		851		578
Other	861		645		584
Corporate	377		375		366
	$	45,101	$	46,494	$	19,101